STOCK TITAN
  1. Home
  2. News
  3. CDTX

Cidara Therapeutics Inc - CDTX STOCK NEWS

Welcome to our dedicated news page for Cidara Therapeutics (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cidara Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cidara Therapeutics's position in the market.

News
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Cidara Therapeutics, Inc. reported financial results for Q4 and full year 2023, highlighted key achievements in their Cloudbreak® platform and REZZAYO® program, including approvals in the EU and UK. The company presented new data at various medical meetings and completed enrollment in a Phase 3 trial in China. Revenue increased, cash reserves grew, and net losses decreased compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
Rhea-AI Summary
Cidara Therapeutics, a biotechnology company, received a delinquency notice from Nasdaq for failing to file its Annual Report on Form 10-K. The company plans to submit its compliance plan and has implemented a 1-for-20 reverse stock split to maintain its listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Cidara Therapeutics Announces Reverse Stock Split
Rhea-AI Summary
Cidara Therapeutics, a biotechnology company, announced a 1-for-20 reverse stock split of its common stock. The reverse split will be effective on April 23, 2024, with trading on a split-adjusted basis starting on April 24, 2024. This decision was made following a stockholder vote and board approval to enhance the stock's value and reduce the number of outstanding shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
stock split
News
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
Rhea-AI Summary
Cidara Therapeutics, Inc. (CDTX) announced promising preclinical data on its drug-Fc conjugate (DFC) immunotherapies at the AACR Annual Meeting. The multispecific CD73/PD-1 DFC showed improved tumor reduction over PD-1 monotherapy, CCR5-targeting DFC demonstrated efficacy in colorectal cancer, and CBO421 outperformed oleclumab in triple-negative breast cancer cell lines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
none
-
News
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024
Rhea-AI Summary
Cidara Therapeutics, Inc. to present preclinical data on drug-Fc conjugate candidates at AACR Annual Meeting, including CD73/PD-1, CCR5, and CBO421 DFCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
conferences
-
News
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
Rhea-AI Summary
Cidara Therapeutics, Inc. (CDTX) receives an $11.14 million milestone payment from Mundipharma following the European approval of REZZAYO™ for the treatment of invasive candidiasis. The approval was based on positive results from the ReSTORE Phase III clinical trial, demonstrating statistical non-inferiority to the standard of care. Cidara plans to advance its Cloudbreak platform for the development of targeted immunotherapies, with a focus on cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
News
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
Rhea-AI Summary
Cidara Therapeutics, Inc. (Nasdaq: CDTX) announces that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has approved REZZAYO (rezafungin acetate) for the treatment of invasive candidiasis in adults, expanding treatment options for patients globally. The approval follows positive results from the ReSTORE Phase III clinical trial, demonstrating statistical non-inferiority for weekly-dosed rezafungin compared to the standard of care. Cidara has partnered with Mundipharma, entitled to receive a $2.8 million milestone payment for the MHRA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
none
-
News
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
Rhea-AI Summary
Cidara Therapeutics, Inc. (Nasdaq: CDTX) announced the approval of REZZAYO (rezafungin acetate) in the European Union (EU) for the treatment of invasive candidiasis in adults. The approval is based on the positive results from the pivotal ReSTORE Phase III clinical trial, supported by the STRIVE Phase II clinical trials and an extensive nonclinical development program. Cidara is entitled to receive a milestone payment of approximately $11.14 million from Mundipharma for the European Medicines Agency (EMA) approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
-
News
Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
Rhea-AI Summary
Cidara Therapeutics, Inc. (Nasdaq: CDTX) announced promising preclinical data on its novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress, showcasing significant tumor growth reduction and superior anti-tumor activity to monotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
none
News
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
Rhea-AI Summary
Cidara Therapeutics, Inc. (Nasdaq: CDTX) has completed enrollment in the Phase 3 ReSTORE trial in China evaluating the efficacy and safety of rezafungin as a treatment for candidemia and invasive candidiasis. The trial included 52 patients and is expected to provide top-line data in Q2 2024. Rezafungin has received FDA approval in the U.S. and a positive CHMP opinion in the EU, with a final decision expected soon. Melinta Therapeutics has exclusive commercialization rights to REZZAYOTM in the U.S., and Mundipharma has rights in all other geographies except the U.S. and Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
clinical trial
Stock CDTX logo
Cidara Therapeutics Inc

Nasdaq:CDTX

CDTX Rankings

#4764 Ranked by Market Cap
#734 Ranked by Stock Gains
N/A Ranked by Dividends

CDTX Stock Data

73.40M
76.81M
7.53%
30.63%
0.22%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About CDTX

cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.